






Choose Tango™ Neo from Ellex, and you'll be able to move effortlessly between SLT and YAG modes, which means you can treat patients with glaucoma and secondary cataract with maximum accuracy and optimal efficacy.



■ INTUITIVE USER INTERFACE

10.1 inch capacitive touchscreen tablet to efficiently switch between **SLT** and **YAG** modes



- 400 µm single spot size
- 3 nanosecond pulse duration
- Fully titratable energy control delivering more with less

Nd:YAG Lower, more efficient energy levels

- Rapid repetition rate up to 3 shots per second
- Single, double or triple pulse
- Precise and powerful Nd:YAG beam output profile with very low optical breakdown in air of 1.8 mJ*
- Wide ranging YAG Posterior Offset
- Incremental energy selection

ILLUMINATION

With exceptional illumination & pristine optical view of the anterior segment





A highly accurate two-point focusing system with a tolerance range of ± 8 µm in YAG mode delivers pinpoint precision.



THREE KEY TREATMENT MODALITIES



Clinically proven as a first line therapy for Primary Open Angle Glaucoma and ocular hypertension¹

- Eradicates compliance issues with medication²
- An efficacious and REPEATABLE treatment option
- EGS, NICE Recommended first line therapy^{3,4}

Tango™ Neo features Ellex's proprietary SLT technology — with superior energy control, and an homogenous 400 μm diameter aiming beam clearly traversing a large portion of the full width of the Trabecular Meshwork.

LIGHT STUDY IN FIGURES¹



652
PATIENTS RANDOMLY
ASSIGNED TO SLT

ASSIGNED TO SLT (329 PATIENTS) OR EYE DROPS (323 PATIENTS).



5X

TIMES LESS MEDICATION-DROP
RELATED ADVERSE EVENTS* WITH SLT.

*Aesthetic side effect or ocular reactions



74.2%

OF SLT PATIENTS REACHED TARGET IOP AND WERE DROP-FREE AT 36 MONTHS.



More information about SLT: www.glaucoma-laser-assisted-solutions.com

Nd:YAG







LASER PERIPHERAL IRIDOTOMY

For the YAG treatment of angle closure glaucoma, Tango™ Neo with burst mode provides double or triple laser impact for most efficient creation of a laser peripheral iridotomy within an iris crypt.

Full thickness penetrating treatments or staged therapy following initial thinning with a photocoagulating laser for thicker irides.





YAG POSTERIOR CAPSULOTOMY

Tango™ Neo's Nd:YAG mode features an Ultra Gaussian laser beam profile with rapid rise time providing a stable and efficient laser energy output, pulse after pulse.

This efficent laser formation produces Tango™ Neo's very low Nd:YAG optical breakdown resulting in superior clinical performance at lower energy levels.

A wide ranging YAG posterior offset of up to 500 μ m displacing the laser treatment beam proximity to IOL.



TECHNICAL SPECIFICATIONS

SLT MODE

Pulse Width

Q-switched, frequency doubled Nd:YAG Laser Source

Wavelength

Energy 0.3 to 2.6 mJ per pulse, continuously variable

Burst Mode Single pulse only

Spot Size 400 µm

Aiming Beam Red 635 nm, adjustable intensity

YAG MODE

Pulse Width

Laser Source Q-switched Nd:YAG

Wavelength 1064 nm

0.3 to 10 mJ per pulse, continuously variable Energy

4 ns

Burst Mode 1, 2 and 3 pulses

per burst, selectable

Spot Size 8 µm

Offset (Anterior and Posterior) 0, -500 to +500 μm

Red 635 nm adjustable intensity **Aiming Beam**

© Lumibird Medical Group 2023. Tango™ Neo is a trademark of Ellex Medical Pty Ltd and the Lumibird Medical Group. All rights reserved.

COMMON FEATURES SPECIFICATION

Repetition Rate Up to 3 Hertz

Magnification Optimized for enhanced anterior segment

visualization

Illumination Cooling Air cooled

User Interface

Electrical Requirements

Weight

Dimensions (HxWxD)

Standard Accessories

Optional Accessories

Halogen

Capacitive 10.1" touch screen tablet

100-240 VAC, 50/60 Hz, 800 VA

31 kg. 68 lbs (laser only)

57 x 75 x 44 cm, 23 x 30 x 18 inches (laser only)

Total Solution™ table, safety glasses, laser

safety sign, dust cover

SLT Laser lens, capsulotomy and iridotomy laser lenses, footswitch, five-position magnification changer, beam splitter, «C» mount camera adapter, video camera

adapter, co-observation tube

Specifications are subject to change without notice. Non contractual pictures.

BIBLIOGRAPHY

- (1) Gazzard G, Konstantakopoulou E, Garway-Heath D,et al. Selective laser trabeculoplasty versus eye drops for first-line treatment of ocular hypertension and glaucoma (LiGHT): a multicentre randomised controlled trial. Lancet 2019, Mar 9;393(10180):1505-16.
- (2) Reardon G, Kotak S, Objective assessment of compliance and persistence among patients treated for glaucoma and ocular hypertension: a systematic review. Epub 2011 Sep 23. PMID: 22003282; PMCID: PMC3191921.
- (3) Garg A, Vickerstaff V, et al. Efficacy of Repeat Selective Laser Trabeculoplasty in Medication-Naive Open-Angle Glaucoma and Ocular Hypertension during the LiGHT Trial. Ophthalmology. 2020 Apr;127(4):467-476. doi: 10.1016/j.ophtha.2019.10.023. Epub 2019 Oct 30. PMID: 32005561.
- (4) European Glaucoma Society Terminology and Guidelines for Glaucoma, 5th Edition. Br J Ophthalmol. 2021 Jun;105(Suppl 1):1-169. doi: 10.1136/bjophthalmol -2021-egsguidelines. PMID: 34675001.



www.lumibird-medical.com



WARNING - VISIBLE AND INVISIBLE LASER **RADIATION - AVOID EXPOSURE TO BEAM**



Headquarters

Lumibird Medical 1, Rue du Bois Joli - CS40015 63808 Cournon d'Auvergne – France Tel: +33 (0)4 73 745 745

Manufacturer

Ellex Medical Pty Ltd 3-4 Second Avenue Mawson Lakes, SA 5095 Australia Tel: +61 (0)8 7074 8200 ISO 13485 : 2016



LUMIBIRD® MEDICAL

QUANTEL MEDICAL - ELLEX - OPTOTEK MEDICAL